Ladenburg Thalmann Financial Services Inc. Boosts Position in Stemline Therapeutics Inc (STML)

Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Stemline Therapeutics Inc (NASDAQ:STML) by 810.6% during the fourth quarter, Holdings Channel reports. The firm owned 12,694 shares of the biopharmaceutical company’s stock after buying an additional 11,300 shares during the period. Ladenburg Thalmann Financial Services Inc. owned approximately 0.07% of Stemline Therapeutics worth $136,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in STML. Candriam Luxembourg S.C.A. acquired a new stake in Stemline Therapeutics during the third quarter valued at approximately $2,783,000. Baker BROS. Advisors LP acquired a new stake in Stemline Therapeutics during the third quarter valued at approximately $3,612,000. State Treasurer State of Michigan acquired a new stake in Stemline Therapeutics during the third quarter valued at approximately $217,000. Perceptive Advisors LLC acquired a new stake in Stemline Therapeutics during the fourth quarter valued at approximately $115,000. Finally, Bogle Investment Management L P DE acquired a new stake in Stemline Therapeutics during the fourth quarter valued at approximately $1,015,000. 37.76% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Shares of Stemline Therapeutics Inc (NASDAQ:STML) opened at 8.45 on Friday. Stemline Therapeutics Inc has a 12-month low of $4.06 and a 12-month high of $14.60. The company’s market cap is $151.69 million. The stock has a 50 day moving average of $7.88 and a 200 day moving average of $10.58.

ILLEGAL ACTIVITY WARNING: This report was first posted by Web Breaking News and is the property of of Web Breaking News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at http://www.webbreakingnews.com/2017/03/26/ladenburg-thalmann-financial-services-inc-boosts-position-in-stemline-therapeutics-inc-stml.html.

STML has been the subject of several recent research reports. Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Wedbush restated an “outperform” rating and issued a $15.00 price target on shares of Stemline Therapeutics in a report on Tuesday, December 6th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, February 2nd. Ladenburg Thalmann Financial Services set a $41.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Monday, March 20th. Finally, HC Wainwright set a $34.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Monday, February 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and an average price target of $24.33.

In related news, COO Kenneth Hoberman sold 9,110 shares of the firm’s stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $13.82, for a total transaction of $125,900.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ivan Bergstein sold 17,980 shares of the firm’s stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $125,680.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,356 shares of company stock valued at $531,879. 16.70% of the stock is owned by company insiders.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics Inc (NASDAQ:STML).

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.